http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112384506-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4152 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 |
| filingDate | 2019-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2023-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2023-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112384506-B |
| titleOfInvention | Indoline-1-carboxamide compound, its preparation method and its application in medicine |
| abstract | The invention relates to a new indoline-1-carboxamide compound that regulates or inhibits the activity of vascular endothelial cell growth factor receptor (VEGFR), its preparation method and its application in medicine. Specifically, it relates to a compound represented by general formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt thereof, and the application of the compound or a pharmaceutically acceptable salt thereof A method for treating and/or preventing related diseases mediated by VEGFR, especially tumors, and a method for preparing the compound or a pharmaceutically acceptable salt thereof. The present invention also relates to the preparation of the compound or its pharmaceutically acceptable salt or the pharmaceutical composition containing the compound or its pharmaceutically acceptable salt for the treatment and/or prevention of related diseases mediated by VEGFR, especially tumor use in medicines. Wherein the substituents of the general formula (I) are the same as defined in the description. |
| priorityDate | 2018-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 181.